Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itolizumab plus corticosteroids for initial treatment of acute graft versus host disease
2024-516064-28-00Phase 3Completed
- Sponsor
- Equillium, Inc.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Itolizumab + corticosteroids with Placebo + corticosteroids (2 arms). Primary endpoint: Complete Response rate at Day 29. Started Aug 2024; status: completed.
02
Drugs
itolizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2024-516064-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516064-28-00.